Navigation Links
FDA Alert: New USP Standards for Heparin Products Will Result in Decreased Potency
Date:10/1/2009

Adjustments may be needed to achieve desired anticoagulant effect in some patients

New Heparin to Ship Starting October 8

SILVER SPRING, Md., Oct. 1 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today alerted health care professionals to a change in heparin manufacturing that is expected to decrease the potency of the common blood-clotting drug.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

To ensure the quality of heparin and to guard against potential contamination, the United States Pharmacopeia (USP), a nonprofit standards-setting organization, adopted new manufacturing controls for heparin. These changes include a modification of the reference standard for the drug's unit dose.

Manufacturers in the United States label the amount of heparin included in their products based on USP standards. The changes adopted by the USP for the heparin unit dose match the World Health Organization's International Standard (IS) unit dose definition that has been in use in Europe for many years. The revised USP reference standard and unit definition for heparin is about 10 percent less potent than the former USP unit.

A unit is the measure of a drug's activity in the body. For heparin, a unit dose is the measure of the drug's ability to block the blood's natural clotting ability (anticoagulation). Heparin's potency is determined by the dose of the drug required to produce a specific level of anticoagulation.

Manufacturers for the U.S. market have begun to make heparin using the new USP standard. While the USP manufacturing controls take effect Oct. 1 for production, the FDA has asked that they not ship this new product to customers until Oct. 8, 2009, or later. The delay will give health care providers and facilities time to learn about the changes and to make adjustments to their pharmacy procedures and dosing practices, according to John Jenkins, M.D. director of the Office of New Drugs in the FDA's Center for Drug Evaluation and Research.

"Although the FDA-approved labeling for heparin has not changed, including the recommended doses, it is essential that health care professionals be aware of the potential difference in potency between the old and new vials of heparin when administering the drug," said Jenkins.

Four companies market heparin in the United States. APP, the largest manufacturer, markets heparin in vials; Hospira markets heparin in intravenous bags, vials, and syringes; Baxter markets heparin in intravenous bags, and B. Braun markets heparin in intravenous bags. The FDA has asked that all manufacturers identify their new products to help pharmacies and health care professionals differentiate it from the former product.

Prescription and over-the-counter medicines available in the United States must generally meet USP's public standards, when such standards exist. The revised standards for heparin are contained in a new USP monograph.

The monograph was revised, in part, in response to a 2007- 2008 incident of heparin contamination involving a manufacturing step in China. The contaminated heparin was associated with deaths and other adverse events in the United States. The monograph was changed to include a test for the contaminant.

For more information

FDA Alert to Health Care Professionals

http://www.fda.gov//Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm184502.htm

USP Heparin Information

http://www.usp.org/hottopics/heparin.html

    Media Inquiries: Karen Riley, 301-796-4674, karen.riley@fda.hhs.gov
    Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
2. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
3. Real-World Study Showed Cost Savings for VTE Prophylaxis with Enoxaparin Compared with Unfractionated Heparin (UFH)
4. Heparin Use Prior to Endoscopic Vein Harvest Improves Graft Patency in Off-Pump Coronary Artery Bypass Patients
5. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
6. ISAR-REACT 3 Pits Bivalirudin vs. Unfractionated Heparin in PCI
7. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
8. WaveSense Diabetes Products Safe from Maltose Inaccuracy Risks
9. BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products, Now Available
10. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
11. Processed Tomato Products May Protect Against Inflammation, According to a Study Presented at the Experimental Biology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... 2016  Diagnostic imaging has been on the ... that these tests cause health care costs to spike. However, ... well as the adoption of new guidelines are ... that help health care providers cut costs, while helping patients ... a renowned authorized reseller of the medical industry,s ...
(Date:5/5/2016)... Research and Markets has announced the addition of the  "Market ... to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Emission Tomography (PET) scanner and cyclotron install base in the ... France , Germany , ... United Kingdom . Along with the current ...
(Date:5/5/2016)... DUBLIN , May 5, 2016 ... Markets has announced the addition of the  ... Highlights - 2016"  report to their ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The latest ... Landscape Highlights - 2016, provides comprehensive ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... United Collection Bureau, Inc. (UCB) announces Sarah ... than 15 years of experience within the healthcare revenue cycle industry. With a primary ... Director of Patient Financial Services at Spectrum Health. While at Spectrum Health, Clark helped ...
(Date:5/5/2016)... ... ... Lung Institute will celebrate its three-year anniversary on May 14 by giving away ... month of May. To date, the Lung Institute has treated over 2,000 people at their ... testament to the success of this treatment and to the patients who refuse to give ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... finalists and winners Tuesday evening, May 3, at the 2016 ISE® Central Executive ... Scott Pettigrew, Vice President and Chief Security Officer of HMS, was selected as ...
(Date:5/5/2016)... ... ... May flowers, summer is just around the corner. Summer means a lot of different things ... ability to play all day and night. Parents often lament the coming of summer as ... Summer also means trips to the beach, backyard cookouts, fireworks on the Fourth of July, ...
(Date:5/5/2016)... ... 05, 2016 , ... ACLS Certification Institute, a leading provider ... program, giving participants incentive for spreading the word about the Institute’s certification and ... professionals share resources with their friends and colleagues,” said Vonda Andrews, ACLS Certification ...
Breaking Medicine News(10 mins):